Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
about
Venetoclax: First Global Approval.Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.Clinical pharmacokinetics of oral drugs in the treatment of multiple myeloma.Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.
P2860
Q38853500-1DDCF7B1-71DD-4D8A-A21B-99B72BFF4577Q39038037-40BB71F2-4AC4-4B96-87F4-B99BCDE4BABDQ39040977-82794C83-C9AB-422E-A99D-DBA0A4FAADC4Q39137457-36DEF583-F649-4E05-A501-8AB77ABB9905Q39177442-7F2E46D8-6F8C-4C71-91E3-7DAEDDF0A215Q39200835-9DE6938A-8B64-4C64-BCC1-93041E192879Q40537266-435515F8-D5F6-4B88-9D55-16E072AEFAE1Q40597634-BDEB6B94-91D3-43E2-BFD1-4B8D66BB950FQ45057327-49EED79B-EF59-4AC8-9609-426588278E6CQ46633482-A5213E61-E09C-4BE0-94D3-1486B4894A80Q47553423-D432A5C8-5F7C-4A74-BE12-5FC2D8906488Q47610956-E4AF555E-DFBB-4942-9B7D-69B29CDA7942Q48146110-7A79CE65-F658-402D-B6D2-9937D7D76F5EQ48203285-B1C8312C-C1CE-43AD-A19A-EFA1BED4A409Q48257454-6E2FBCA4-70A5-4965-A0F1-7BB2CC7DD25BQ50119590-FA0AB4E6-C464-4EDA-B07E-5C1A01B36BBEQ51007604-B403DAAC-217A-48CF-A34D-A1C255EE19D2Q51280033-F50C020C-8AAC-44BA-81F5-C40C5FAEFB60Q51842580-637A2022-B502-4DC9-B63E-7F00A600CEDA
P2860
Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Evaluation of Rifampin's Trans ...... ngle- and Multiple-Dose Study.
@en
Evaluation of Rifampin's Trans ...... ngle- and Multiple-Dose Study.
@nl
type
label
Evaluation of Rifampin's Trans ...... ngle- and Multiple-Dose Study.
@en
Evaluation of Rifampin's Trans ...... ngle- and Multiple-Dose Study.
@nl
prefLabel
Evaluation of Rifampin's Trans ...... ngle- and Multiple-Dose Study.
@en
Evaluation of Rifampin's Trans ...... ngle- and Multiple-Dose Study.
@nl
P2093
P2860
P356
P1476
Evaluation of Rifampin's Trans ...... ngle- and Multiple-Dose Study.
@en
P2093
Ahmed Hamed Salem
David Chien
Shekman L Wong
P2860
P304
P356
10.1002/JCPH.730
P577
2016-03-07T00:00:00Z